New Manufacturing Process Patent for Ox-1

Theracryf

16/04/2026 07:00

RNS Number : 6260A

Theracryf PLC

16 April 2026

 

 

16 April 2026

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1

Additional patent submission provides potential 20-year protection

Strengthens long-term commercial value and partnering potential

 

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that it has filed a new process patent covering novel aspects of the manufacturing method for its lead programme, a selective orexin-1 receptor antagonist (Ox-1) being developed for addiction.

 

The patent, when granted, will protect for 20 years from filing, potentially to 2046, extends the commercial exclusivity for the Ox-1 blocker across major markets, substantially beyond the life of the existing global Composition of Matter patent. The filing follows recent successful manufacturing optimisation and scale-up work during which several novel and efficiency-enhancing chemical process improvements were identified.

 

Process patents provide an additional barrier to generic competition, as alternative manufacturing routes must be developed to avoid infringement, which are typically not undertaken by competitors. The filing builds on the Company's recently announced strengthening of the Ox-1 patent estate across key global markets and forms part of its broader strategy to establish a robust intellectual property portfolio as the programme advances towards completing the data required for clinical readiness later in 2026.

 

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

 

"This new process patent submission further strengthens the intellectual property protection surrounding our lead asset and has the potential to extend its commercial exclusivity very substantially.

 

As TheraCryf progresses swiftly towards clinical development, expanding our broad and defensible patent portfolio is central to maximising the long-term commercial value of the programme and its attractiveness to potential partners."

 

-Ends-

 

Enquiries

 

TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, COO
+44 (0)1625 315 090
enquiries@theracryf.com
Singer Capital Markets (NOMAD & Joint Broker)Phil Davies/ Patrick Weaver
+44 (0)20 7496 3000
Turner Pope Investments (Joint Broker)
Guy McDougall / Andy Thacker
+44 (0)20 3657 0050
Northstar Communications (Investor Relations)
Sarah Hollins
+44 (0)113 730 3896
sarah@northstarcommunications.co.uk

 

About TheraCryf

 

TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need within central nervous system (CNS) disorders.

 

The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.

 

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

 

The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.

 

For further information, visit: https://theracryf.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
RESFLFLVSRIELIR